Showing results (71-80 of 88) with videos related to
Sort By:
Pageof 9
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2020
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosisMinh Le, Charles Malpas, Sifat Sharmin, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.Frontiers in Neurology|January 7, 2021
New Algorithms Improving PML Risk Stratification in MS Patients Treated With NatalizumabInmaculada Toboso, Amalia Tejeda-Velarde, Roberto Alvarez-Lafuente, et al.Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2023
Disability accrual in primary and secondary progressive multiple sclerosisSam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2023
Comparative effectiveness in multiple sclerosis: A methodological comparisonIzanne Roos, Ibrahima Diouf, Sifat Sharmin, et al.Pageof 9